Scott J. Antonia, MD, PhD, instructor, Duke University School of Medicine, member, Duke Cancer Institute, discusses investigational immunotherapy combinations in stage III non–small cell lung cancer (NSCLC).
Scott J. Antonia, MD, PhD
Advertisement
Articles by Scott J. Antonia, MD, PhD
Scott J. Antonia, MD, PhD, instructor, Duke University School of Medicine, member, Duke Cancer Institute, discusses the promise of immunotherapy in patients with non–small cell lung cancer.
Phase II Clinical Trial of Intratumoral Dendritic Cells Injections and Neoadjuvant Radiotherapy in Resectable Soft Tissue Sarcomas
ByShailaja Raj MD,Gregory Springett MD PhD,Daniel Indelicato MD,Marilyn Bui, MD, PhD,Anthony Conley MD,Sergio Lavilla-Alonso PhD,Xiuhua Zhao MS,Dungsa Chen PhD,Randy Haysek MD,Ricardo Gonzalez MD,Douglas Letson MD,Steven Eric Finkelstein MD PhD,Alberto Chiappori MD,Dimitry Gabrilovitch MD PhD,Scott J. Antonia, MD, PhD
Neoadjuvant radiation with dendritic cell injections has the potential to be safe, effective, and immunogenic in high-grade soft tissue sarcoma and needs to be confirmed in randomized larger clinical trials.
Scott J. Antonia, MD, PhD, chair of the Department of Thoracic Oncology at Moffit Cancer Center, discusses immunotherapies that are emerging in the field of lung cancer.
Advertisement
Latest Updated Articles
Dr. Antonia on Emerging Immunotherapies in Lung CancerPublished: December 2nd 2016 | Updated:
Dr. Antonia on the Promise of Immunotherapy in NSCLCPublished: May 29th 2019 | Updated:
Dr. Antonia on Investigational Immunotherapy Combinations in Stage III NSCLCPublished: June 21st 2019 | Updated:
Phase II Clinical Trial of Intratumoral Dendritic Cells Injections and Neoadjuvant Radiotherapy in Resectable Soft Tissue SarcomasPublished: February 22nd 2018 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
5